Compare MGN & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGN | PDSB |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0M | 49.5M |
| IPO Year | 2025 | N/A |
| Metric | MGN | PDSB |
|---|---|---|
| Price | $1.80 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 33.0K | ★ 592.3K |
| Earning Date | 01-29-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $13,484,571.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.30 | $0.70 |
| 52 Week High | $8.63 | $2.20 |
| Indicator | MGN | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.68 |
| Support Level | N/A | $0.86 |
| Resistance Level | N/A | $0.93 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 11.26 |
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.